logo-loader
NASDAQ:SLRX

Salarius Pharmaceuticals

Market:
NASDAQ
Market Cap:
$8.87 m
Price
0.65 USD
Change
-3.07%
52 weeks high
24.45
52 weeks low
0.56

In brief

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. The company’s lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Pediatric Rare Disease Designation by the U.S. Food and Drug Administration.